BAP1 Antibody (C-4) is an IgG₁ κ mouse monoclonal BAP1 antibody (also designated BRCA1 associated protein 1 antibody, or BAP1 gene product antibody) that detects the BAP1 protein of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA. BAP1 Antibody (C-4) is available as both the non-conjugated anti-BAP1 antibody form, as well as multiple conjugated forms of anti-BAP1 antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor^® conjugates. Mutations within the BRCA1 gene, localized to chromosome 17q, are believed to account for approximately 45% of families with increased incidence of both early-onset breast cancer and ovarian cancer. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a RING domain near the N-terminus and appears to encode a tumor suppressor. BARD1 (BRCA1-associated RING domain protein 1) and BAP1 (BRCA1-associated protein 1) have both been shown to bind to the N-terminus of BRCA1 and are potential mediators of tumor suppression. BARD1 contains an N-terminal RING domain and three tandem ankyrin repeats. The C-terminus of BARD1 contains a region with sequence homology to BRCA1, termed the BRCT domain. BAP1 is a ubiquitin hydrolase and has been shown to enhance BRCA1-mediated cell growth suppression.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

References:

1. Familial breast-ovarian cancer locus on chromosome 17q12-q23.  |  Narod, SA., et al. 1991. Lancet. 338: 82-3. PMID: 1676470
2. Linkage of early-onset familial breast cancer to chromosome 17q21.  |  Hall, JM., et al. 1990. Science. 250: 1684-9. PMID: 2270482
3. BRCA1 mutations in primary breast and ovarian carcinomas.  |  Futreal, PA., et al. 1994. Science. 266: 120-2. PMID: 7939630
4. Breast cancer gene offers surprises.  |  Nowak, R. 1994. Science. 265: 1796-9. PMID: 8091205
5. Identification of a RING protein that can interact in vivo with the BRCA1 gene product.  |  Wu, LC., et al. 1996. Nat Genet. 14: 430-40. PMID: 8944023
6. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains.  |  Jin, Y., et al. 1997. Proc Natl Acad Sci U S A. 94: 12075-80. PMID: 9342365
7. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.  |  Thai, TH., et al. 1998. Hum Mol Genet. 7: 195-202. PMID: 9425226
8. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.  |  Jensen, DE., et al. 1998. Oncogene. 16: 1097-112. PMID: 9528852

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-BAP1 Antibody (C-4) has 319 citations in a variety of scientific publications.

Primary antibodies like Anti-BAP1 Antibody (C-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.